Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab

Abstract Background The optimal treatment sequence for patients with advanced BRAF V600 mutant melanoma is unknown. BRAF/MEK inhibition (BRAF/MEKi), single agent anti‐PD‐1 (aPD‐1) antibodies and combination immune checkpoint inhibition with nivolumab and ipilimumab (niv/ipi) are all approved; howeve...

Full description

Bibliographic Details
Main Authors: Justin C. Moser, Danli Chen, Siwen Hu‐Lieskovan, Kenneth F. Grossmann, Shiven Patel, Sarah V. Colonna, Jian Ying, John R. Hyngstrom
Format: Article
Language:English
Published: Wiley 2019-12-01
Series:Cancer Medicine
Subjects:
anti‐PD‐1 antibodies
BRAF
dabrafenib
melanoma
nivolumab/ipilimumab
pembrolizumab
Online Access:https://doi.org/10.1002/cam4.2625

Internet

https://doi.org/10.1002/cam4.2625

Similar Items